Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals announce today preliminary results from a Phase I Clinical Study of Oratecan – an oral form of the approved intravenously administered cancer drug irinotecan, with HM30181, a potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Read more>
• Adds GLP and cGMP Capabilities to Kinex Platform
• Generates Opportunity to Execute Against Global Manufacturing Opportunities
Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed. Read more>
Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company’s KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company’s third IND to be allowed by the US FDA in the past 12 months.
Kinex Pharmaceuticals announced today that Dr. Jean-Pierre Sommadossi has elected to step down from the Board of Directors of Kinex but will continue to support the company as a Senior Advisor to the CEO. After an extensive search, the Board has appointed Michael P. Murphy to the Board of Directors to fill the Board seat vacated by Dr. Sommadossi.
Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol – an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Read more>